Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.28% is 106% above its 5-year average of 0.62%, near the low end of its 5-year range (0.00%–123.69%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.64% below its 12-month average of 1.85%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.28%.
DEBT TO ASSETS RATIO
1.28%
DEBT TO ASSETS RATIO AVG TTM
1.85%
DEBT TO ASSETS RATIO AVG 3Y
0.95%
DEBT TO ASSETS RATIO AVG 5Y
0.62%
DEBT TO ASSETS RATIO AVG 10Y
0.50%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-30.64%
CURRENT VS 3Y AVG
+35.18%
CURRENT VS 5Y AVG
+106.21%
CURRENT VS 10Y AVG
+158.84%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 592 covered companies
CURRENT VS SECTOR MEDIAN
+1182.11%
vs the sector median at left
TuHURA Biosciences, Inc.
Market Cap
$120.24M
Debt to Assets Ratio
1.28%
TTM Avg
1.85%
3Y Avg
0.95%
5Y Avg
0.62%
Market Cap
$121.25M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.83M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.57M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$116.54M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.79M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $120.24M | 1.28% | 1.85% | 0.95% | 0.62% |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | 0.12% | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.83M | 0.00% | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $123.66M | 0.10% | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | 0.09% | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | 0.19% | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $124.95M | 0.02% | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.79M | 0.09% | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | 0.09% | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | 0.64% | N/A | N/A | N/A |
Debt/Assets
1.3%
Debt/Equity
0.02
Current Ratio
0.18
Interest Coverage
-50.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.28% |
| 2026-03-31 | 1.54% |
| 2025-12-31 | 2.56% |
| 2025-09-30 | 2.25% |
| 2025-06-30 | 1.61% |
| 2025-03-31 | 1.12% |
| 2024-12-31 | 1.01% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 123.69% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 1.05% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 2.67% |
| 2020-12-31 | 2.31% |
| 2020-09-30 | 1.91% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
